Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Phibro Animal Health Corporation Class A

PAHC

Phibro Animal Health Corp is a world-wide diversified animal health and mineral nutrition company. It strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. It develop, manufacture and market products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. It has three segments Animal Health, Mineral Nutrition, and Performance Products. Majority of revenue comes from Animal Health segment. Animal health products are anti-bacterials, anticoccidials, nutritional specialty products, and vaccines, and vaccine adjuvants that help improve the animal's health.

Last trade $34.82
Day change -$0.20 (-0.57%)
Day range $34.29 – $35.69
Volume 58,712
Market cap $1.42B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.42B
Price / earnings
13.84×
Price / book
3.4×
Price / sales
0.92×
EV / sales
1.35×
EV / EBITDA
8.49×

Profitability

Earnings per share
$2.53
Return on assets
6.78%
Return on equity
24.59%
Dividend yield
1.37%

Liquidity and leverage

Debt / equity
1.76×
Current ratio
3.2×
Quick ratio
1.28×
Cash ratio
0.26×

Cash flow

Price / cash flow
16.58×
Price / free cash flow
65.61×
Free cash flow
$21.67M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PAHC, quarterly periods
Line itemQ1 FY2027 Sep 30, 2026Q4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q3 FY2025 Mar 31, 2025Q2 FY2025 Dec 31, 2024
Revenue$386.77M$396.75M$383.54M$373.91M$363.89M$378.7M$347.83M$309.26M
Cost of revenue$258.24M$262.35M$257.87M$241.25M$244.11M$268.69M$243.26M$207.39M
Gross profit$128.54M$134.4M$125.68M$132.66M$119.78M$110.01M$104.57M$101.87M
Selling, general and administrative$78.9M$86.24M$81.02M$82.33M$68.52M$76.29M$71.05M$76.34M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$78.9M$86.24M$81.02M$82.33M$68.52M$76.29M$71.05M$76.34M
Operating income$49.64M$48.16M$44.65M$50.33M$51.26M$33.72M$33.52M$25.53M
Interest expense-$11.29M-$10.18M-$10.43M$0-$12.06M-$8.61M-$9.36M$0
Income before taxes$38.78M$32.34M$32.31M$36.43M$36.27M$23.85M$29.69M$4.84M
Income taxes$9.26M$10.63M$8.29M$8.97M$9.74M$6.62M$8.81M$1.65M
Net income$29.52M$21.71M$24.02M$27.46M$26.53M$17.22M$20.88M$3.19M
Net income attributable to common shareholders$29.52M$21.71M$24.02M$27.46M$26.53M$17.22M$20.88M$3.19M
EBITDA$63.22M$61.5M$57.1M$63.22M$64.09M$46.13M$46.13M$37.11M
Basic earnings per share$0.73$0.54$0.59$0.68$0.65$0.42$0.52$0.08
Diluted earnings per share$0.72$0.53$0.59$0.67$0.65$0.42$0.51$0.08

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Should You Continue to Hold ALGN Stock in Your Portfolio?

Align Technology has gained 25.4% over the past year, outperforming the S&P 500, driven by Invisalign portfolio expansion into younger patients and complex cases, plus strategic DSO partnerships. However, the stock faces headwinds from currency volatility and intense competition from traditional braces and lower-priced clear aligner alternatives. The company holds a Zacks Rank #3 (Hold) with 2026 EPS estimates revised down 1.5% to $11.12.

Zacks Investment Research

Here's Why You Should Retain NVST Stock in Your Portfolio for Now

Envista Holdings (NVST) has gained 24% over the past year, outperforming its industry, driven by international expansion, new product launches, and strong earnings beats. The company achieved 9% adjusted EBITDA growth and 25% EPS growth. However, fierce competition, weakness in China sales, and foreign exchange headwinds pose risks to future revenue and margin expansion.

Zacks Investment Research

Should You Continue to Retain Bruker Stock in Your Portfolio?

Bruker Corporation (BRKR) is well-positioned for growth driven by strong diagnostics and biosystems revenue, favorable European demand, and a $140 million cost-savings target by 2026 aimed at expanding margins by 250-300 basis points. However, uneven U.S. academic demand, macroeconomic uncertainty, and trade policy volatility present headwinds. The stock carries a Zacks Rank #3 (Hold) rating with a 3.4% earnings yield.

Zacks Investment Research

Is Now the Right Time to Hold Labcorp Stock in Your Portfolio?

Labcorp Holdings (LH) has surged 48.2% year-to-date, driven by expansion in specialty testing markets, AI and automation initiatives, and six consecutive quarters of margin expansion. However, currency headwinds, intense competition, and acquisition-related execution risks could limit future growth. The company maintains a Zacks Rank #3 (Hold) with a 5% earnings yield.

The Motley Fool

Phibro: 3 Key Takeaways for Long-Term Investors

Phibro reported Q1 FY2027 net sales of $386.8 million, up 6% year-over-year, with strong growth in higher-margin segments like Mineral Nutrition (+17%) and Performance Products (+16%). However, poultry market softness pressured short-term demand as producer margins tightened. Management prioritizes reducing excess inventory to improve free cash flow and pay down debt, while expecting protein producer margins to recover as feed costs decline.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.12 per share
Declared
Nov 3, 2026
Ex-dividend
Nov 25, 2026
Pay date
Dec 16, 2026
Ex-dividendAmount / sharePay dateType
Sep 2, 2026$0.12Sep 23, 2026recurring
Jun 3, 2026$0.12Jun 24, 2026recurring
Mar 4, 2026$0.12Mar 25, 2026recurring
Nov 26, 2025$0.12Dec 17, 2025recurring
Sep 3, 2025$0.12Sep 24, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.